| rivaroxaban / Generic mfg. |
| Completed | N/A | 19076 | Canada, Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939), Standard care treatment for VTE prophylaxis | Bayer, Janssen Research & Development, LLC | Venous Thromboembolism | 06/11 | 04/13 | | |
NCT01444586: Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) |
|
|
| Completed | N/A | 2293 | RoW | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | 08/13 | 07/14 | | |
NCT01855100: Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) |
|
|
| Completed | N/A | 131 | Europe | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Scientific Affairs, LLC | Venous Thrombosis | 11/14 | 12/14 | | |
| Completed | N/A | 3388 | RoW | Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.) | Bayer, Janssen Research & Development, LLC | Venous Thromboembolism | 03/15 | 01/16 | | |
XALIA, NCT01619007: Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy |
|
|
| Completed | N/A | 5145 | Canada, Europe, RoW | Rivaroxaban (Xarelto, BAY59-7939), Standard of care | Bayer, Janssen Research & Development, LLC | Deep Vein Thrombosis, Venous Thrombosis | 03/15 | 07/15 | | |
SATORI, NCT01805544: Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication |
|
|
| Completed | N/A | 113 | Europe | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Venous Thrombosis | 04/15 | 06/15 | | |
XYRIS, NCT01523418: Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) |
|
|
| Withdrawn | N/A | 0 | RoW | Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Prophylaxis, Thromboembolism, Venous, Total Knee Replacement, Total Hip Replacement | 11/16 | 11/16 | | |
